Prelude Therapeutics Ownership | Who Owns Prelude Therapeutics?
Prelude Therapeutics Ownership Summary
Prelude Therapeutics is owned by 47.14% institutional investors, 9.06% insiders, and 43.80% retail investors. Orbimed advisors is the largest institutional shareholder, holding 14.40% of PRLD shares. T. Rowe Price Health Sciences is the top mutual fund, with 1.35% of its assets in Prelude Therapeutics shares.
PRLD Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Prelude Therapeutics | 47.14% | 9.06% | 43.80% |
| Sector | Healthcare Stocks | 88.01% | 8.90% | 3.09% |
| Industry | Biotech Stocks | 109.70% | 8.77% | -18.47% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Orbimed advisors | 10.91M | 14.40% | $41.56M |
| Baker bros. advisors lp | 10.12M | 13.37% | $38.57M |
| Deerfield management company, l.p. (series c) | 4.13M | 5.46% | $15.75M |
| Boxer capital | 2.57M | 3.39% | $9.79M |
| Blackrock | 1.07M | 1.41% | $4.07M |
| Vanguard group | 1.01M | 1.33% | $3.85M |
| Price t rowe associates inc /md/ | 891.30K | 1.18% | $3.40M |
| Massachusetts financial services co /ma/ | 522.38K | 0.69% | $1.99M |
| Geode capital management | 361.95K | 0.48% | $1.38M |
| Morgan stanley | 287.35K | 0.38% | $1.09M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Orbimed advisors | 10.91M | 0.83% | $41.56M |
| Boxer capital | 2.57M | 0.52% | $9.79M |
| Baker bros. advisors lp | 10.12M | 0.49% | $38.57M |
| Deerfield management company, l.p. (series c) | 4.13M | 0.26% | $15.75M |
| Bridgeway capital management | 123.60K | 0.01% | $470.92K |
| Exchange traded concepts | 64.41K | 0.00% | $82.12K |
| Renaissance | 206.60K | 0.00% | $787.15K |
| Massachusetts financial services co /ma/ | 522.38K | 0.00% | $1.99M |
| Td asset management | 160.65K | 0.00% | $612.08K |
| Tower research capital llc (trc) | 7.06K | 0.00% | $26.91K |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Rhumbline advisers | 166.83K | 0.00% | 154.83K |
| Jacobs levy equity management | 17.76K | 0.00% | 17.76K |
| Dimensional fund advisors lp | 29.07K | - | 14.77K |
| Deutsche bank ag\ | 14.62K | - | 14.62K |
| Massachusetts financial services co /ma/ | 522.38K | 0.00% | 14.23K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Sio capital management | - | - | -320.39K |
| Millennium management | - | - | -101.85K |
| Price t rowe associates inc /md/ | 891.30K | 0.00% | -50.67K |
| Renaissance | 206.60K | 0.00% | -38.20K |
| Kennedy capital management | - | - | -35.28K |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Deutsche bank ag\ | 14.62K | - | 14.62K | $55.70K |
| Mirae asset global etfs | 8.13K | 0.00% | 8.13K | $30.99K |
| Corebridge financial | 7.09K | 0.00% | 7.09K | $27.02K |
| Russell investments group | 1.48K | - | 1.48K | $5.64K |
| Pnc financial services group | 64.00 | - | 64.00 | $244.00 |
Sold Out
| Holder | Change |
|---|---|
| Nelson, van denburg & campbell wealth management group | -1.00 |
| Capital performance advisors llp | -8.00 |
| Nisa investment advisors | -2.10K |
| Qube research | -3.13K |
| American group | -7.33K |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2024 | 71 | 14.52% | 35,754,682 | 5.42% | 47 | 2.35% | 37 | 48.00% | 19 | -9.52% |
| Jun 30, 2024 | 62 | 6.90% | 33,917,495 | -0.86% | 44 | 1.39% | 25 | 13.64% | 21 | -4.55% |
| Mar 31, 2024 | 58 | 1.75% | 34,212,156 | -1.48% | 56 | 1713434.09% | 22 | -35.29% | 22 | 57.14% |
| Dec 31, 2023 | 57 | -3.39% | 34,725,237 | -5.16% | - | 0.00% | 34 | 13.33% | 14 | -12.50% |
| Sep 30, 2023 | 59 | 7.27% | 36,614,222 | -5.02% | 65 | 1.00% | 30 | -25.00% | 16 | 100.00% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| T. Rowe Price Health Sciences | 741.44K | 1.35% | -24.79K |
| Vanguard Total Stock Mkt Idx Inv | 720.43K | 1.31% | - |
| iShares Russell 2000 ETF | 379.93K | 0.69% | -58.00 |
| Biotech Growth Ord | 346.50K | 0.63% | - |
| MFS New Discovery I | 327.70K | 0.60% | - |
| Vanguard Institutional Extnd Mkt Idx Tr | 207.51K | 0.38% | - |
| T. Rowe Price Small-Cap Value | 168.61K | 0.31% | -90.00 |
| Fidelity Small Cap Index | 147.71K | 0.27% | 11.37K |
| Bridgeway Ultra-Small Company Market | 137.50K | 0.25% | 52.50K |
| iShares Russell 2000 Value ETF | 125.49K | 0.23% | - |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Dec 31, 2024 | Vaddi Krishna | CEO | Buy | $6.04K |
| Dec 30, 2024 | Vaddi Krishna | CEO | Buy | $12.00K |
| Dec 23, 2024 | Combs Andrew | Chief Chemistry Officer | Buy | $82.00K |
| Dec 20, 2024 | Combs Andrew | Chief Chemistry Officer | Buy | $3.54K |
| Dec 19, 2024 | Lim Bryant David | CLO, Interim CFO, Corp Sec. | Buy | $22.64K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2024 Q4 | 3 | - |
| 2024 Q3 | - | - |
| 2024 Q2 | - | - |
| 2024 Q1 | - | - |
| 2023 Q4 | - | - |
PRLD Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools